📢Recommendations for essential #medicines for #MultipleSclerosis in #low-resource settings have been published by an international, multi-disciplinary panel, supported by the MS International Federation (#MSIF).

The process was supported by the #Cochrane #MS , who led the research work and McMaster University GRADE Centre, who took the methodological lead.

➡️ Read more about these new recommendations:

MSIF: https://www.msif.org/news/2025/01/21/new-recommendations-support-advocacy-for-improved-access-to-ms-treatments/

An explainer I published last year: https://neurontosomething.wordpress.com/2024/07/31/multiple-sclerosis-global-health-and-access-to-essential-healthcare/

What are the benefits and risks of different treatments that could delay or slow the progression of progressive #MultipleSclerosis?

This #SystematicReview looked at the evidence from 23 #MS studies involving 10,167 people.
Read the full review and plain language summary in the #CochraneLibrary -
https://buff.ly/3MPIsEQ

For a blog post explaining some of the background of the collaboration that went into this work: https://neurontosomething.wordpress.com/2024/07/31/multiple-sclerosis-global-health-and-access-to-essential-healthcare/

#MS #MSIF #WHO #Cochrane

A personal PoV on issues of #globalhelath and #evidencebasedmedicine in the context of #multiplesclerosis #MRI and #access to #essentialmedicines

#MS #MSIF #WHO #Cochrane

https://neurontosomething.wordpress.com/2024/07/31/multiple-sclerosis-global-health-and-access-to-essential-healthcare/

As per the WHO multiple sclerosis affects around 2.3 million people globally.

#WorldMultipleSclerosisDay

#LifewithMS #WorldMSDay #MultipleSclerosis #msif #visionproblems #memoryloss #Medeaz